Your session is about to expire
← Back to Search
CAR T-cell Therapy
Long-Term Safety of Gene-Modified Cell Therapy for Cancer
Phase 2
Waitlist Available
Research Sponsored by Kite, A Gilead Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
Study Summary
This trial is looking at the safety of a gene-modified cell therapy product, specifically for neurologic, autoimmune, hematologic, and infection-related adverse events, as well as secondary malignancies. They will also be looking at the growth, development, and sexual maturity of pediatric and adolescent subjects treated with the product.
Who is the study for?
This trial is for people who have had blood or other cancers and were treated with gene-modified cells in previous Kite-sponsored studies. They should be able to follow the study plan and agree to all required check-ups. Participants must understand and sign a consent form.Check my eligibility
What is being tested?
The study aims to assess the long-term effects of several gene therapies (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, KITE-585, etc.) previously administered to participants in earlier trials by Kite Pharma.See study design
What are the potential side effects?
While specific side effects are not listed here, gene therapy can commonly include immune reactions, potential changes in blood counts, fatigue, fever, and could potentially lead to secondary cancers.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Height of Pediatric and Adolescent Participants
Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)
Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)
+3 moreSecondary outcome measures
Cause of Death
Peripheral B-cell and Lymphocytes Levels for Immune Reconstitution
Rate of Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL)
+2 moreTrial Design
7Treatment groups
Experimental Treatment
Group I: KITE-718Experimental Treatment1 Intervention
All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.
Group II: KITE-585Experimental Treatment1 Intervention
All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.
Group III: KITE-439Experimental Treatment1 Intervention
All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.
Group IV: KITE-363Experimental Treatment1 Intervention
All participants who previously received KITE-363 in the parent study will be enrolled in this arm for long-term follow-up.
Group V: KITE-222Experimental Treatment1 Intervention
All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.
Group VI: Brexucabtagene Autoleucel (KTE-X19)Experimental Treatment1 Intervention
All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.
Group VII: Axicabtagene Ciloleucel (KTE-C19 )Experimental Treatment1 Intervention
All participants who previously received axicabtagene ciloleucel (KTE-C19 ) in the parent study will be enrolled in this arm for long-term follow-up.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axicabtagene Ciloleucel
2015
Completed Phase 2
~490
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
CAR T-cell therapies involve genetically modifying a patient's T-cells to express chimeric antigen receptors (CARs) that specifically target cancer cell antigens, leading to the direct destruction of cancer cells. This personalized approach harnesses the body's immune system to fight cancer more effectively.
Other common treatments include immune checkpoint inhibitors, which block proteins that prevent T-cells from attacking cancer cells, and targeted therapies that inhibit specific molecules involved in cancer cell growth and survival. These mechanisms are vital for cancer patients as they offer tailored treatment options that can improve outcomes and reduce side effects compared to traditional therapies.
Find a Location
Who is running the clinical trial?
Kite, A Gilead CompanyLead Sponsor
44 Previous Clinical Trials
3,401 Total Patients Enrolled
Kite Study DirectorStudy DirectorKite, A Gilead Company
29 Previous Clinical Trials
2,759 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: KITE-363
- Group 2: KITE-439
- Group 3: KITE-222
- Group 4: Axicabtagene Ciloleucel (KTE-C19 )
- Group 5: Brexucabtagene Autoleucel (KTE-X19)
- Group 6: KITE-585
- Group 7: KITE-718
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger